95 related articles for article (PubMed ID: 9783979)
1. Absence of expression of transforming growth factor-beta type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca.
Kundu SD; Kim IY; Zelner D; Janulis L; Goodwin S; Engel JD; Lee C
J Urol; 1998 Nov; 160(5):1883-8. PubMed ID: 9783979
[TBL] [Abstract][Full Text] [Related]
2. Restoration of expression of transforming growth factor-beta type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2'-deoxycytidine.
Zhang Q; Rubenstein JN; Liu VC; Park I; Jang T; Lee C
Life Sci; 2005 Jan; 76(10):1159-66. PubMed ID: 15620579
[TBL] [Abstract][Full Text] [Related]
3. The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
Ripley D; Tang XM; Ma C; Chegini N
Gynecol Oncol; 2001 May; 81(2):301-9. PubMed ID: 11330966
[TBL] [Abstract][Full Text] [Related]
4. Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.
Perry K; Wong L; Liu V; Park I; Zhang Q; Rejen V; Huang X; Smith ND; Jovanovic B; Lonning S; Teicher BA; Lee C
Urology; 2008 Jul; 72(1):225-9. PubMed ID: 18295867
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells.
Engel JD; Kundu SD; Yang T; Lang S; Goodwin S; Janulis L; Cho JS; Chang J; Kim SJ; Lee C
Urology; 1999 Jul; 54(1):164-70. PubMed ID: 10414746
[TBL] [Abstract][Full Text] [Related]
6. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
7. Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.
Yamada SD; Baldwin RL; Karlan BY
Gynecol Oncol; 1999 Oct; 75(1):72-7. PubMed ID: 10502429
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
Okamoto M; Oyasu R
Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
[TBL] [Abstract][Full Text] [Related]
9. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
10. Captopril restores transforming growth factor-beta type II receptor and sensitivity to transforming growth factor-beta in murine renal cell cancer cells.
Miyajima A; Asano T; Hayakawa M
J Urol; 2001 Feb; 165(2):616-20. PubMed ID: 11176447
[TBL] [Abstract][Full Text] [Related]
11. Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
Park B; Jang JS; Park K
Int J Oncol; 2000 Sep; 17(3):473-8. PubMed ID: 10938386
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
Kominsky SL; Doucet M; Brady K; Weber KL
J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta1 and renal cell cancer: cell growth, mRNA expression and protein production of cytokines.
Shimabukuro T; Ohmoto Y; Naito K
J Urol; 2003 May; 169(5):1865-9. PubMed ID: 12686863
[TBL] [Abstract][Full Text] [Related]
14. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
15. Cellular response to latent TGF-beta1 is facilitated by insulin-like growth factor-II/mannose-6-phosphate receptors on MS-9 cells.
Ghahary A; Tredget EE; Mi L; Yang L
Exp Cell Res; 1999 Aug; 251(1):111-20. PubMed ID: 10438576
[TBL] [Abstract][Full Text] [Related]
16. The spatiotemporal expression of TGF-beta1 and its receptors during periosteal chondrogenesis in vitro.
Mizuta H; Sanyal A; Fukumoto T; Fitzsimmons JS; Matsui N; Bolander ME; Oursler MJ; O'Driscoll SW
J Orthop Res; 2002 May; 20(3):562-74. PubMed ID: 12038632
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Paterson IC; Matthews JB; Huntley S; Robinson CM; Fahey M; Parkinson EK; Prime SS
J Pathol; 2001 Apr; 193(4):458-67. PubMed ID: 11276004
[TBL] [Abstract][Full Text] [Related]
18. FK506, transforming growth factor-beta1 and mesangial matrix synthesis: parallels and differences compared with cyclosporine A.
Waiser J; Dell K; Kreutzkamp J; Böhler T; Budde K; Peters H; Neumayer HH
Cytokine; 2006 Jan; 33(2):59-65. PubMed ID: 16458528
[TBL] [Abstract][Full Text] [Related]
19. Potential role of transforming growth factor beta1 in drug resistance of tumor cells.
Stoika R; Yakymovych M; Souchelnytskyi S; Yakymovych I
Acta Biochim Pol; 2003; 50(2):497-508. PubMed ID: 12833174
[TBL] [Abstract][Full Text] [Related]
20. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type.
Ramp U; Jaquet K; Reinecke P; Schardt C; Friebe U; Nitsch T; Marx N; Gabbert HE; Gerharz CD
J Urol; 1997 Jun; 157(6):2345-50. PubMed ID: 9146668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
